Vera Therapeutics Inc Cl A (VERA) Stock Price, Quote & News

Company Profile

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with serious immunological diseases. The company's lead product candidate consists of atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A n...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 770 0077

Website: veratx.com

Address:

2000 Sierra Point Parkway, Suite 1200, Brisbane, United States

GTDFLY Nov. 14 at 6:23 PM

$VERA I do feel like some large bio player may have eyes on snatching this up too. Time will tell. Least I can feel ok being long here into and in '26 vs who knows with rest the market being sus at best considering the amount of pamping and propping lol. This could buck any real corrections rest the indices endure next year. Will see. Cheers catch up next week. ✌️

0 · Reply

GTDFLY Nov. 14 at 2:09 PM

$VERA happy Friday yall! Have a great day and weekend! Markets cold but hopefully this remains hot! 👍💪

0 · Reply

Irish_lass Nov. 13 at 4:48 PM

$VERA Are we having fun yet?

0 · Reply

GTDFLY Nov. 13 at 2:19 PM

$VERA gm yall! Lets keep this green flowing shall we?! 👀

0 · Reply

GTDFLY Nov. 12 at 8:29 PM

$VERA beautiful day! Maybe that 90PT is indeed doable next year.

0 · Reply

OptionRunners Nov. 12 at 4:42 PM

$VERA Buyer of the December 19th $30 calls (ITM) 3,000 times for $3.95

0 · Reply

GTDFLY Nov. 12 at 2:40 PM

$VERA 30.55 lets keep on chuggin!

0 · Reply

GTDFLY Nov. 11 at 8:55 PM

$VERA 30s! Lets work on 35s then 40s next shall we?!

0 · Reply

G101SPM Nov. 11 at 8:22 PM

$VERA 29.78 +2.03 Holding long position https://stocktwits.com/G101SPM/message/635070933 BRIEF: %): The Co. submits BLA to FDA through Accelerated Approval Program for Atacicept for the treatment of adults with IgA nephropathy.

0 · Reply

GTDFLY Nov. 11 at 6:57 PM

$VERA lets go 30 break!

0 · Reply

Vera Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit

Nov 7, 2025, 6:27 PM EST - 9 days ago

Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy

Nov 7, 2025, 4:05 PM EST - 9 days ago

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 6, 2025, 11:26 PM EST - 10 days ago

Vera Therapeutics, Inc. (VERA) Discusses Interim Results of ORIGIN Phase 3 Trial of Atacicept for IgA Nephropathy Transcript

Nov 6, 2025, 9:51 AM EST - 10 days ago

Vera Therapeutics Announces Positive ORIGIN Phase 3 Data for Atacicept in IgA Nephropathy Presented at ASN Kidney Week 2025 and Published in the New England Journal of Medicine

Nov 5, 2025, 7:29 AM EST - 11 days ago

Vera Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

Oct 22, 2025, 8:00 AM EDT - 25 days ago

Vera Therapeutics to Host an Investor Call and Webcast to Provide an ORIGIN 3 Update on November 6, 2025 at 4:30 pm ET

Oct 17, 2025, 9:12 AM EDT - 4 weeks ago

Vera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week 2025

Sep 5, 2025, 5:45 AM EDT - 2 months ago

Vera Therapeutics, Inc. (VERA) Presents at Cantor Global Healthcare Conference 2025 Transcript

Aug 26, 2025, 4:05 PM EDT - 2 months ago

Vera Therapeutics to Participate at Upcoming Investor Conferences

Aug 5, 2025, 7:00 AM EDT - 3 months ago

Vera Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Jul 10, 2025, 7:05 PM EDT - 4 months ago

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 4, 2025, 4:05 PM EDT - 5 months ago

Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Jun 3, 2025, 6:30 AM EDT - 5 months ago

Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans

Jun 2, 2025, 9:01 AM EDT - 5 months ago

Kidney Health-Focused Vera Therapeutics Stock Price Spikes On Heels Of Successful Trial Data

Jun 2, 2025, 8:45 AM EDT - 5 months ago

Vera shares skyrocket as kidney disease drug succeeds in late-stage trial

Jun 2, 2025, 6:30 AM EDT - 5 months ago

Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy

May 15, 2025, 2:46 PM EDT - 6 months ago

Vera Therapeutics: Huge Catalyst Upcoming For Kidney Disease Drug

May 6, 2025, 8:00 AM EDT - 6 months ago

Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

Apr 3, 2025, 8:00 AM EDT - 8 months ago

Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN

Feb 27, 2025, 8:00 AM EST - 9 months ago

Vera Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

Feb 26, 2025, 8:25 AM EST - 9 months ago

Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Jan 22, 2025, 6:46 AM EST - 10 months ago

Top 3 Health Care Stocks That Could Blast Off This Quarter

RDNT VKTX

Jan 7, 2025, 4:05 PM EST - 11 months ago

Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Oct 29, 2024, 8:21 PM EDT - 1 year ago

Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock

Oct 28, 2024, 5:37 PM EDT - 1 year ago

Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock

Oct 28, 2024, 10:33 AM EDT - 1 year ago

Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years

Oct 26, 2024, 7:30 PM EDT - 1 year ago

Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024

Oct 4, 2024, 1:45 PM EDT - 1 year ago

Vera: Potential First Of Atacicept As A B-Cell Modulator For IgAN Patients

Oct 2, 2024, 6:30 AM EDT - 1 year ago

Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases

Oct 2, 2024, 6:30 AM EDT - 1 year ago

Vera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024

Sep 3, 2024, 7:49 AM EDT - 1 year ago

Load Up on Adobe Stock and These 2 Others This September, J.P. Morgan Says

ADBE CZR KYTX

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Vera Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

Jul 22, 2024, 8:52 AM EDT - 1 year ago

Vera Therapeutics' Atacicept: A Potential Game-Changer In IgA Nephropathy

Jun 11, 2024, 4:01 PM EDT - 1 year ago

Vera Therapeutics Appoints Christy J. Oliger to Board of Directors

Jun 7, 2024, 4:05 PM EDT - 1 year ago

Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

May 28, 2024, 8:00 AM EDT - 1 year ago

Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)

May 25, 2024, 9:40 AM EDT - 1 year ago

Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress

May 9, 2024, 8:00 AM EDT - 1 year ago

Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

Mar 20, 2024, 7:30 AM EDT - 1 year ago

Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 28, 2024, 4:20 PM EST - 1 year ago

Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference

Feb 2, 2024, 8:00 AM EST - 1 year ago

Vera Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Feb 1, 2024, 4:05 PM EST - 1 year ago

Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares in Public Offering of Class A Common Stock

Jan 29, 2024, 11:50 PM EST - 1 year ago

Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock

Jan 25, 2024, 6:30 AM EST - 1 year ago

Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy

Jan 8, 2024, 8:01 AM EST - 2 years ago

Vera Therapeutics Announces Appointment of Industry Veterans Robert Brenner, M.D. as Chief Medical Officer and William D.

Dec 27, 2023, 8:00 AM EST - 2 years ago

Vera Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Nov 9, 2023, 8:00 AM EST - 2 years ago

Vera Therapeutics Provides Business Update and Reports Third Quarter Financial Results

Nov 4, 2023, 10:00 AM EDT - 2 years ago

Vera Therapeutics Presents Positive Data from Phase 2b ORIGIN Study Showing Resolution of Hematuria in Majority of Patients at the American Society of Nephrology Kidney Week 2023

Oct 30, 2023, 8:00 AM EDT - 2 years ago

Vera Therapeutics Scheduled to Present at November Investor Conferences

GTDFLY Nov. 14 at 6:23 PM

0 · Reply

GTDFLY Nov. 14 at 2:09 PM

$VERA happy Friday yall! Have a great day and weekend! Markets cold but hopefully this remains hot! 👍💪

0 · Reply

Irish_lass Nov. 13 at 4:48 PM

$VERA Are we having fun yet?

0 · Reply

GTDFLY Nov. 13 at 2:19 PM

$VERA gm yall! Lets keep this green flowing shall we?! 👀

0 · Reply

GTDFLY Nov. 12 at 8:29 PM

$VERA beautiful day! Maybe that 90PT is indeed doable next year.

0 · Reply

OptionRunners Nov. 12 at 4:42 PM

$VERA Buyer of the December 19th $30 calls (ITM) 3,000 times for $3.95

0 · Reply

GTDFLY Nov. 12 at 2:40 PM

$VERA 30.55 lets keep on chuggin!

0 · Reply

GTDFLY Nov. 11 at 8:55 PM

$VERA 30s! Lets work on 35s then 40s next shall we?!

0 · Reply

G101SPM Nov. 11 at 8:22 PM

0 · Reply

GTDFLY Nov. 11 at 6:57 PM

$VERA lets go 30 break!

0 · Reply

Longbuy1 Nov. 11 at 6:14 PM

$VERA analyst average price target 68.88$ low being 48$ high of 100$.

0 · Reply

Longbuy1 Nov. 11 at 3:44 PM

$VERA see a continuation untill we hot 32$

0 · Reply

Longbuy1 Nov. 10 at 11:16 PM

$VERA $WVE Vera gonna be rocking again tomorrow

0 · Reply

Longbuy1 Nov. 10 at 8:42 PM

$VERA another big buy just happened, this might soar tomorrow.

1 · Reply

biotechworld Nov. 10 at 8:30 PM

$VERA if institutional holding is 112% and short interest of 20% , it is definitely short squeeze material.. stay tuned...

1 · Reply

biotechworld Nov. 10 at 8:13 PM

$VERA added today again. full position.

0 · Reply

notreload_ai Nov. 10 at 5:22 PM

$VERA has submitted its application for atacicept, a potential breakthrough IgAN treatment that successfully reduced proteinuria in the Phase 3 ORIGIN 3 trial. https://notreload.xyz/vera-therapeutics-submits-atacicept-bla-for-igan-accelerated-approval/

0 · Reply

Longbuy1 Nov. 10 at 5:00 PM

$VERA lol

0 · Reply

GTDFLY Nov. 10 at 4:49 PM

$VERA pretty excited so don't mind me lol 😆, although watch for that 30 break and if so.... Actually shocked there is over 10m short here. Ballzy lol.

0 · Reply

GTDFLY Nov. 10 at 4:46 PM

$VERA people beginning to take notice. Break 30 all shorty heck breaks loose by the looks

0 · Reply

GTDFLY Nov. 10 at 4:12 PM

$VERA if this breaks 30s could really trigger some clown shorts to scurry lol. Oh I wouldn't be upset with that lol

0 · Reply

GTDFLY Nov. 10 at 4:01 PM

$VERA Shares Outstanding 63.93M Public Float 48.61M % of Float Shorted 20.07% As per marketwatch.com 👀

0 · Reply

Market Cap	1.81B
Revenue (ttm)	0.00
Net Income (ttm)	-152.15M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.19

Volume	1,250,300
Avg Vol	1,518,886
Day's Range	N/A - N/A
Shares Out	63.82M
Stochastic %K	61%
Beta	1.22
Analysts	Strong Sell
Price Target	$62.85